Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jeff Liter
Early-stage decisions that shape cell therapy development
Early-stage cell therapy companies face a series of process, workflow, and platform decisions well before IND, and each one shapes the likelihood of a successful clinical program. This panel discussion examines those decisions and the trade-offs behind them across various modalities, such as CAR-T, TIL, TCR, NK cell, and HSC-based therapies. Drawing on real-world examples, the panel explains how early technical choices affect comparability risk, regulatory expectations, and development timelines.
244 A phase 1 study of novel transposon-based BAFF CAR-T cells (LMY-920) for treatment of relapsed or refractory non-hodgkin lymphoma (NHL)
http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.
Luminary and UNC enter into a License Agreement for an Optimized Dual Targeting CAR designed for solid tumors
Luminary Tx and UNC enter into a formal License Agreement for clinical development of an Optimized CSPG4 Dual Targeting CAR designed to treat solid tumors! MINNEAPOLIS, MN, UNITED STATES, June 13, 2023/ EINPresswire.com/ -- Luminary Therapeutics and University of North Carolina enter into a formal License Agreement for clinical development of novel CSPG4 target and Optimized Dual Targeting CAR design to treat solid tumors Luminary Therapeutics (Luminary Tx) and University of North Carolina...
Gamma Delta: Two Phase 1 INDs Approved Announces Jeff Liter CEO Luminary Therapeutics
If you can't view this video, your browser does not support HTML5 videos To view this video please enable JavaScript, and consider upgrading to a web browser thatsupports HTML5 video Jeff Liter, MBS, CEO of Luminary Therapeutics discusses Gamma Delta: Two Phase 1 INDs Approved 1 day 9 Views Category: Description: Gamma Delta: Two Phase 1 INDs Approved Announces Jeff Liter CEO Luminary Therapeutics By Jeff Liter, MBS, CEO of Luminary Therapeutics We currently have two Phase 1 INDs approved:...
Dr. Joseph Eid to join Luminary Therapeutics as Chief Medical Officer
There were 1,896 press releases posted in the last 24 hours and 312,867 in the last 365 days. Luminary announces a new Chief Medical Officer MINNEAPOLIS, MN, UNITED STATES, December 7, 2022 / EINPresswire.com/ -- Luminary is announcing the appointment of Dr. Joseph Eid as the organization's new fractional Chief Medical Officer (CMO). Dr. Eid succeeds Dr. Arek Duddek who has taken on new responsibilities at the Mayo Clinic.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jeff
Contact Jeff, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack